Belvedere Trading’s Relay Therapeutics RLAY Stock Holding History

Belvedere Trading’s Portfolio RLAY Stock Details RLAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-2,000	Closed	-$32.9K	–	1079
2023 Q1	$32.9K	Buy	+2,000	New	+$35.9K	﹤0.01%	646

Other funds holding RLAY

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Belvedere Trading's RLAY Position: Q2 2023 in Review

Belvedere Trading sold out of Relay Therapeutics (RLAY) in Q2 2023, closing a stake of 458 shares — an estimated $7.54K sold.

Belvedere Trading first reported a position in RLAY in Q1 2023 and held it in 1 quarter. The position peaked at $7.54K in Q1 2023. 161 funds tracked by Wall St. Rank hold RLAY as of Q2 2023.

Belvedere Trading reported no remaining Relay Therapeutics position as of Q2 2023 after selling out during the quarter.
Belvedere Trading sold 458 Relay Therapeutics shares in Q2 2023, an estimated $7.54K.
Belvedere Trading first reported a position in Relay Therapeutics in Q1 2023 and held it in 1 quarter.
Belvedere Trading's Relay Therapeutics position peaked at $7.54K in Q1 2023.
161 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2023.

Based on Belvedere Trading's 13F filing for Q2 2023, filed 8 Aug 2023.